THDBH120
/ Tonghua Dongbao, WuXi AppTec
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
February 15, 2026
A novel GIPR/GLP-1R dual agonist improves systemic metabolism through differentially regulating inflammation and lipid metabolism in obesity.
(PubMed, J Adv Res)
- "Both GLP-1R and GIPR are important in mediating the beneficial effects of dual receptors on systemic metabolism. THDBH120 is a novel long-acting dual GIPR/GLP-1R agonist that has potential clinical applications."
Journal • Diabetes • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
June 27, 2025
Phase II Study of THDBH120 Injection in Overweight or Obese Subjects
(clinicaltrials.gov)
- P2 | N=276 | Recruiting | Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd
New P2 trial • Obesity
June 13, 2025
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM
(clinicaltrials.gov)
- P1 | N=49 | Completed | Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
April 30, 2025
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With Obesity
(clinicaltrials.gov)
- P1 | N=36 | Completed | Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd
New P1 trial • Genetic Disorders • Obesity
December 20, 2024
A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of THDBH120 Injection in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=72 | Completed | Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd
New P1 trial
1 to 5
Of
5
Go to page
1